--(www.USEquityNews.com)-- 06/16/2008 - Healthcare industry alert provided by U.S. Equity News. Biotechnology company Gilead Sciences Inc. (NASDAQ: GILD) said recently its experimental inhaled cystic fibrosis treatment continued meeting safety goals in an ongoing late-stage study. The inhaled version of aztreonam lysine is already under review by the Food and Drug Administration and Gilead expects a decision by Sept. 16. The most recent study results are from an open-label, ongoing Phase III clinical trial involving patients from a prior late-stage study. The goal of the ongoing study is to further evaluate the safety of patients. Patients will be followed for an overall treatment period of 18 months and the study will be complete by the fourth quarter.
Maxygen Inc. (NASDAQ: MAXY) warned Friday that Amgen Inc. may sue the company for patent infringement relating to Maxygen's Maxy-G34 drug candidate. Maxy-G34 is designed to be the improved version of granulocyte colony-stimulating factor, or G-CSF, for the treatment of neutropenia, according to a Securities and Exchange Commission filing Friday. Neutropenia is an abnormally low number of neutrophils, a type of white blood cell, in the blood. White blood cells help fight bacterial infections. Maxygen, a Redwood City, Calif.-based biopharmaceutical company, said the U.S. Food & Drug Administration granted a patent to Amgen on June 3 with certain G-CSF claims.
Polydex Pharmaceuticals Limited (NASDAQ: POLXF) has recently reported financial results of operations for the first quarter of fiscal 2009, ending April 30, 2008. As of April 30, 2008, assets of the Company totaled $9,912,545. With liabilities totaling $2,269,766 as of this date, the shareholders' equity of the Company was $7,642,779, or approximately $2.49 per share. Although sales in the first quarter of fiscal 2009, ending April 30, 2008, were slightly less than the comparable period last year, improved gross margins and continued efforts by management to reduce expenses has resulted in a decrease in net loss for the quarter.
TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announced that an independent third party research article in the Journal of Investigative Dermatology has confirmed and corroborated that a TAP incorporated vaccine should be considered as a therapy for the treatment of cancer, in this case, Melanoma. The article, in advance online publication 3 April 2008, titled, "Restoration of the Expression of Transporters Associated with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity," is yet another promising research study that confirms and corroborates the TAP incorporated vaccine. There is now a vast amount of research data supporting and corroborating the initial description of the promising effect of TAP as a cancer therapy and their effect on tumor recognition. For more information, please visit www.stocksjournal.com.
About U.S. Equity News
U.S. Equity News provides information, resources and news services for investors of small-cap, micro-cap and emerging companies. U.S. Equity News distributes RSS news feeds and a free subscription-based newsletter available through its website at www.usequitynews.com.
U.S. Equity News is a financial news distribution service by Equity Solutions, Inc. (www.equityirsolutions.com) that provides a platform for public companies to disseminate important news to key Wall Street interest such as shareholders and new investors. Equity Solutions, Inc. can assist by providing an effective increase in the awareness of a public company's news, development and corporate story through its proprietary network and its financial portal. U.S. Equity News and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.USEquityNews.com.
